Supplementary Table 1: Patient Demographics						
Variable n (%)	**Early HTx (n=60)**			**Late HTx (n=77)**		
Total patients **n = 137**	**AMR** **(n=9)**	**No AMR** **(n=51)**	**p value**	**CAV** **(n=14)**	**No CAV** **(n=63)**	**p value**
Age at HTx (yrs)	**50.1 $\pm$ 13.4**	**53.3 $\pm$ 11.8**	**0.25**	**58.4 $\pm$ 10.6**	**56.1 $\pm$ 9.2**	**0.32**
Male Gender(M:F)	**7 :2**	**40:11**	**0.18**	**11:3**	**49:14**	**0.29**
Ethnicity						
Caucasian	**7**	**35**	**0.12**	**11**	**43**	**0.67**
African American	**2**	**7**	**0.17**	**2**	**10**	**0.35**
Other	**0**	**2**	**1.0**	**1**	**2**	**0.43**
LVAD prior to HTx	**2**	**8**	**0.71**	**3**	**16**	**0.12**
Mean f/u time (yrs)	**1.6 $\pm$ 0.9**	**1.7 $\pm$ 0.7**	**0.55**	**8.9 $\pm$ 4.9**	**10.3 $\pm$ 6.5**	**0.31**
Values presented as mean $\pm$ stdev or (%)						

Supplementary Table 2: Increased levels of Abs to Col-V and KAT are significantly associated with the development of DSA in AMR following HTx				
		DSA+	DSA-	P value
Col-V	AMR+	344 ± 94 (n=7)	176 ± 65 (n=2)	0.03
	AMR-	61 ± 28 (n=8)	56 ± 21 (n=36)	0.92
KAT		DSA+	DSA-	P value
	AMR+	296 ± 71 (n=7)	91 ± 42 (n=2)	0.003
	AMR-	67 ± 24 (n=8)	59 ± 17 (n=36)	0.89

Supplementary Table 3: Increased levels of Abs to Col-V and KAT are significantly associated with the development of DSA in patients with CAV following HTx				
		DSA+	DSA-	P value
Col-V	CAV+	812 ± 142 (n=11)	313 ± 134 (n=3)	0.001
	CAV-	264 ± 76 (n=15)	211 ± 87 (n=40)	0.83
KAT		DSA+	DSA-	P value
	CAV+	796 ± 210 (n=11)	220 ± 78 (n=3)	0.02
	CAV-	196 ± 67 (n=15)	134 ± 104 (n=40)	0.88